This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.
Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW . Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991; 7: 193–198.
Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM . Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268–1275.
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014; 49: 168.
Ringdén O, Klaesson S, Sundberg B, Ljungman P, Lönnqvist B, Persson U . Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992; 9: 19.
Storb R, Deeg HJ, Whitehead J, Farewell V, Appelbaum FR, Beatty P et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 1987; 19: 2608.
Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 1459–1464.
Vigorito A, Campregher P, Storer B, Carpenter PA, Moravec CK, Kiem HP et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVDH. Blood 2009; 114: 702–708.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Smith BR, Parkman R, Lipton J, Nathan DG, Rappeport JM . Efficacy of a short course (four doses) of methotrexate following bone marrow transplantation for prevention of graft-versus-host disease. Transplantation 1985; 39: 326–329.
Hamilton BK, Rybicki L, Haddad H, Abounader D, Yurch M, Majhail NS et al. Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study. Blood Cancer J 2015; 5: e344.
Ramanan R, Boon Ming Lim A, Mason K, Szer J, Ritchie D . Causes and effects of methotrexate dose alterations in allogeneic hematopoietic cell transplantation. Blood 2014; 124: 2460.
Bensinger W, . Stem Cell Trialists’ Collaborative Group. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38: 539–546.
Deotare U, Al-Dawsari G, Couban S, Lipton JH . G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant 2015; 50: 1150–1156.
Rubio MT, Labopin M, Blaise D, Socié G, Rojas Contreras R, Chevallier P et al. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of The European Group For Blood And Marrow Transplantation. Haematologica 2015; 100: 683–689.
Acknowledgements
We thank the non-governmental and non-profit organization ‘Unidos…Asociacion Pro Trasplante de Medula Osea’, in Mexico City, for facilitating most of our patients the acquisition of medications and providing emotional support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Leon-Rodriguez, E., Rivera-Franco, M. & Campos-Castro, A. Is day +1 omission of methotrexate associated with higher incidence of acute GvHD in hematopoietic stem cell transplantation?. Bone Marrow Transplant 52, 772–774 (2017). https://doi.org/10.1038/bmt.2016.359
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.359
This article is cited by
-
Overcoming barriers for the establishment of a consolidated hematopoietic cell transplantation program in a developing country
International Journal of Hematology (2020)